The Trip Report by Beckley Waves
The Trip Report
#1: Dr. Amy Kruse - Investing in Neuroscience & Transformational Technologies

#1: Dr. Amy Kruse - Investing in Neuroscience & Transformational Technologies

Today I am speaking with Dr. Amy Kruse.

She is a neuroscientist, General Partner, and Chief Investment Officer at Satori Neuro, a venture capital fund focused on mental health, neurotechnology, and human flourishing.

Amy earned a Bachelor of Science in Cell and Structural Biology and a Ph.D. in Neuroscience from the University of Illinois at Champaign-Urbana. She went on to serve as a program manager at the Defense Advanced Research Projects Agency (DARPA), where she oversaw the agency’s first performance-oriented neuroscience programs and orchestrated scientific breakthroughs in augmented cognition, accelerated learning, optimized imagery analysis, team neurodynamics, and neuromodulation.

After DARPA, she served as the Vice President and Chief Technology Officer of Cubic Global Defense and Chief Scientific Officer of Optios.

Prior to joining Satori Neuro, Dr. Kruse was a General Partner at Prime Movers Lab, where she led the fund’s life sciences investments in human augmentation and longevity.

In this episode, we talk about:

  • The neuroscience of learning;

  • How to improve human performance and mastery;

  • The connection between meditation and psychedelic research; and

  • The varieties of neurotechnology.

Listen to the episode on Substack, Spotify, Google, or Apple.


Share The Trip Report by Beckley Waves

The Trip Report by Beckley Waves
The Trip Report
The Trip Report is a podcast and newsletter about the business, science, and policy developments of the evolving psychedelic field. While the main organizing theme is psychedelics, it is really about the many different domains that are converging to bring about this field and the assembly of what many believe to be a “New Paradigm” in science, medicine, and our understanding of the human experience. Our goal is to foster an educated and informed psychedelic ecosystem, and to do that, we will feature in-depth conversations with scientists, entrepreneurs, investors and stakeholders at the forefront of the psychedelic renaissance.